posted
This looks like a pretty good little company. Sales and profits increasing nicely. PE below 8 right now. (This in another light volume stock so use caution)
posted
I picked up a starter position, like what I've read on them so far. ty.
-------------------- FurrySound -DD-GLTA-Unless I've quoted a source, I know not what I speak of. YahooIM=FurrySound Posts: 2170 | From: Pennsylvania, USA | Registered: Mar 2004
| IP: Logged |
posted
Actually dipped on the news but again no volume. Will add more tomorrow. The release does not look good: LOTUS PHARMACEUTICALS, INC. Files SEC form 8-K, Non-Reliance on Previous Financials, Audits or Interim Review. But if you read the 8-K it is not bad news.
Posts: 1458 | From: Ohio | Registered: Mar 2004
| IP: Logged |
posted
Trying to add at .82. Private placement of $5 million. Quarterly results should be out soon!
Posts: 1458 | From: Ohio | Registered: Mar 2004
| IP: Logged |
posted
The fourth quater profit will be at least $2.5 million with 2007 year net income of $8.5 million! Making earnings for the year around .17!
Posts: 1458 | From: Ohio | Registered: Mar 2004
| IP: Logged |
posted
Still holding. Down to low .60s. Went as low as mid .50s. Got to hold now. Would buy more but already have enough in this. Earnings should be released in the next month. Last year they announced on April 17 so I am patiently waiting!
Posts: 1458 | From: Ohio | Registered: Mar 2004
| IP: Logged |
posted
Earnings should be this week. Hoping volume will pick up into earnings. Should be at least $2.5 million for the quarter and $8.5 million for the year!
Posts: 1458 | From: Ohio | Registered: Mar 2004
| IP: Logged |
posted
They released there 10K!!!! Blow out quarter and year!!!
From 10K: As a result of these factors, we reported net income of $11,217,128 for 2007 as compared to $4,143,020 for 2006. In 2007 we reported an unrealized gain on foreign currency translation of $1,480,352, an increase of $1,152,784, or approximately 352%, from 2006. We report in U.S. dollars, but the functional currency of Lotus East is the RMB. Translation adjustments result from the process of translating the local currency financial statements into U.S. dollars, with the average translation rates applied to our income statement of 7.6172 RMB to $1.00 in 2007. As a result of this non-cash gain, we reported comprehensive income of $12,697,480, or basic net income per common share of $0.27, for 2007 as compared to $4,470,588, or basic net income per common share of $0.10 for 2006.
Posts: 1458 | From: Ohio | Registered: Mar 2004
| IP: Logged |
posted
.27 net income per share and it closed at .71 today! WOW should be exciting tomorrow!
Posts: 1458 | From: Ohio | Registered: Mar 2004
| IP: Logged |
posted
Volume heavier then normal! But below 200K. They need to issue a press release about full year and fourth quarter results. More people read that then the filing. Might have to wait till Q1. Hopefully today is the start of its move north. Would rather go up slowly anyway. Need volume up above 1 million.
Posts: 1458 | From: Ohio | Registered: Mar 2004
| IP: Logged |
posted
Earnings will be released tomorrow before the bell in a press release! Plus a conference call. I am hoping for forward guidance and some better volume. Dipped today to under 90,000. If volume does not spike tomorrow this still is undiscovered. Might have to wait till Q1.
Posts: 1458 | From: Ohio | Registered: Mar 2004
| IP: Logged |
posted
Revenues for fourth quarter should be about $19.2 million up from about $12.1 million the previoes year. Profit for the fourth quarter should be about $6 million compared to a slight loss the year before.
Great numbers!
Posts: 1458 | From: Ohio | Registered: Mar 2004
| IP: Logged |
posted
Its a long read but worth it. Thanks osubucks for bringing this one to the table. I know it has low volume but after reading this press release that shows a net profit of .26 cents a share, and ALL their 14% debenture debt was paid, this thing could start making some head way. TMAN...
Press Release Source: Lotus Pharmaceuticals, Inc.
Lotus Pharmaceuticals, Inc. Announces Fourth Quarter and Fiscal Year 2007 Results Thursday April 17, 7:00 am ET
BEIJING, April 17 /Xinhua-PRNewswire-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS - News; ''Lotus'' or the ''Company''), a pharmaceutical company in the People's Republic of China ("PRC"), today announced financial results for the fourth quarter and fiscal year ended December 31, 2007.
Fourth Quarter 2007 Highlights -- Total revenues increased to $19.2 million, up 72.7% from the fourth quarter of 2006 -- Gross profit reached $8.3 million, up 234% from the fourth quarter of 2006 -- Gross margin was 43.1%, up from 22.3% in the fourth quarter of 2006 -- Operating income totaled $3.4 million, up from a loss of $0.1 million in the fourth quarter of 2006 -- Net income increased to $5.1 million, or $0.12 per diluted share, up from a loss of $0.2 million, or ($0.00) per diluted share, in the fourth quarter of 2006 -- Excluding non-cash debt financing costs and a gain from the forgiveness of income and value-added taxes, adjusted net income was $3.4 million, or $0.08 per fully diluted share
Full Year 2007 Highlights -- Total revenues increased 57% in 2007 to $56.9 million -- Gross profit increased 130% in 2007 to $23.2 million -- Gross margin was 40.8%, up from 27.8% in 2006 -- Operating income increased 153% to $11.3 million -- Net income increased to $11.2 million, or $0.26 per fully diluted share, up from $4.1 million, or $0.10 per fully diluted share in 2006 -- Excluding non-cash debt financing costs and one-time financial items, adjusted net income was $8.5 million, or $0.19 per fully diluted share, up 34.3% from adjusted net income in 2006
''This was a very successful year for Lotus Pharmaceuticals, both in terms of financial performance and the execution of our strategic initiatives. We achieved significant growth in revenues, due in large part to our strategy of penetrating the direct sales channels into agencies and hospitals and enhancing our production capacity. We also focused on our best selling products, including our hypertension medication VALSARTAN Capsules, and began distributing higher-margin, third-party pharmaceutical products through our existing network,'' said Mr. Zhongyi Liu, Chairman and CEO of Lotus Pharmaceuticals, Inc. ''We will continue to maintain this strategy in the year ahead and plan to explore new markets.''
Fourth Quarter 2007 Results
Lotus Pharmaceutical's total revenue in the fourth quarter was $19.2 million, an increase of 73% on year-over-year basis. This was primarily the result of strong performance associated with the Company's continued efforts to develop its sales distribution channels. Wholesale revenue increased 143% year-over-year to $15.9 million, or 83% of total revenue, and includes the effect of the recording of a $2.2 million sales return allowance in 2006, which reduced 2006 revenues. Other revenue decreased 24% year-over-year to $3.1 million, or 16% of revenue in the fourth quarter of 2007, mainly due to a decrease in third-party manufacturing. Retail revenue was $0.2 million in the fourth quarter of 2007, due to the Company's strategy to sell its traditional Chinese medicines at reduced prices through its retail channel due to quality control concerns.
Gross profit in the fourth quarter of 2007 was $8.3 million, an increase of 234% on year-over-year basis. Gross margin was 43.1%, up from 22.3% in the fourth quarter of 2006, primarily due to production efficiencies as well as the recording of a sales allowance in the fourth quarter of 2006, which decreased revenue by $2.2 million.
Operating expenses in the fourth quarter of 2007 were $4.8 million, up 85% from $2.6 million in the fourth quarter of 2006. This increase was primarily the result of higher selling expenses associated with the Company's sales growth. Research and development expenses were $0.9 million in the fourth quarter of 2007, compared with $0.1 in the fourth quarter of 2006. General and administrative expenses were $0.4 million, down from $0.7 million a year ago. Operating expenses were 25% of total revenue in the fourth quarter of 2007, up from 24% in the fourth quarter of 2006.
Operating income was $3.4 million, compared with an operating loss of $0.1 million in the fourth quarter of 2006.
Net income for the fourth quarter of 2007 was $5.1 million, or $0.12 per diluted share, compared to loss of $0.1 million, or ($0.00) per fully diluted share, in the fourth quarter of 2006. Adjusting net income for non-cash financing costs associated with its convertible notes, and a one-time forgiveness of income and value added taxes of $2.2 million, adjusted net income was $3.4 million, or $0.08 per fully diluted share, in the fourth quarter of 2007, up 68% from adjusted net income of $2.0 million, or $0.05 per fully diluted share, in the fourth quarter of 2006.
Full Year 2007 Results
For the full year 2007, total revenues were $56.9 million, up 57% from $36.2 million in 2006. Wholesale revenue increased 64% in 2007 $41.7 million, or 73% of total revenue, and includes the effect of a $2.2 million reversal of a sales return allowance originally recorded in 2006. Other revenue increased 62% in 2007 to $11.8 million, or 21% of revenue in 2007. Retail revenue was relatively unchanged at $3.5 million. Gross profit for the full year 2007 was $23.2 million, an increase of 130% from $10.1 million in 2006. Gross margin was 40.8%, up from 27.8% in 2006. Operating income was $11.3 million, up 153% from $4.5 million in 2006. Net income for 2007 was $11.2 million, or $0.26 per diluted share, compared to $4.1 million, or $0.10 per diluted share, in 2006. Adjusting net income for non-cash financing costs associated with its convertible notes, the previously mentioned one-time reversal of a sales allowance and a one-time forgiveness of income and value added taxes, adjusted net income was $8.5 million, or $0.19 per fully diluted share, in 2007, up 34% from adjusted net income of $6.3 million, or $0.16 per fully diluted share, in 2006.
Financial Condition
As of December 31, 2007, Lotus had $4.6 million in cash and equivalents, approximately $24.7 million in working capital, secured convertible notes of $2.6 million and $4.7 million in notes payable. Stockholders' equity at December 31, 2007 was $26.6 million, up 126% from $11.8 million at December 31, 2006.
In 2008 the Company received net proceeds from the sale of shares of its Series A Convertible Redeemable Preferred Stock of approximately $4.6 million. The Company used approximately $2.6 million to repay in full all of its outstanding obligations under its 14% secured convertible notes, the remainder will be used for working capital purposes.
2008 Outlook
''In 2008, we expect to see continued growth in sales and anticipate a growing contribution from sales of our proprietary products. We plan to utilize the capital raised in our private placement to fund our exciting new R&D initiatives and to strengthen our sales channels. Additionally, we plan to diversify our products,'' said Mr. Liu. ''We recently completed a $5.0 million private placement financing which provides us with the resources we need to pursue our R&D efforts and pursue strategic acquisitions. Additionally, we plan to use our sales and marketing expertise and the benefits of scale to improve profitability. We believe we are in a very strong position to take advantage of the growing pharmaceutical market in China, and are committed to maximizing value to our shareholders now and in the future.''
Conference Call
The Company will conduct a conference call at 9:00 a.m. Eastern Time on Thursday, April 17, 2008 to discuss the fourth quarter and fiscal year 2007 results. To participate in the live conference call, please dial the following number five to ten minutes prior to the scheduled conference call time: 800-688-0796. International callers should dial 617-614-4070. The Conference ID for this call is 615 756 86. If you are unable to participate in the call at this time, a replay will be available for fourteen days starting on Thursday, April 17, 2008 at 11:00 a.m. Eastern Time. To access the replay, dial 888-286-8010, international callers dial 617-801-6888, conference ID 35016441.
Use of Non-GAAP Financial Information
GAAP results for the three and twelve month periods ended December 31, 2007 and December 21, 2006 include certain non-cash debt financing expenses related to the Company's convertible notes, a $2.2 million one-time reversal of a sales allowance in 2007 that was originally recorded in the fourth quarter of 2006 and a one-time tax relief of $2.2 million recorded in the fourth quarter of 2007. To supplement the Company's condensed consolidated financial statements presented on a GAAP basis, the Company has provided non-GAAP financial information, which are adjusted net income and adjusted earnings per share, excluding the impact of these items in this release. The Company's management believes that these non-GAAP measures provide investors with a better understanding of how the results relate to the Company's historical performance. A reconciliation of adjustments to GAAP results appears below. This additional non-GAAP information is not meant to be considered in isolation or as a substitute for GAAP financials. The non-GAAP financial information that the Company provides also may differ from the non-GAAP information provided by other companies.
About Lotus Pharmaceuticals, Inc.
Lotus Pharmaceuticals, Inc. (''Lotus'') controls and operates Liangfang Pharmaceutical, Ltd. (''Liangfang'') and Enzhe Jiashi Pharmaceutical, Ltd. (''En zhe''), two Chinese pharmaceutical companies located in Beijing (together ''Lotus East''). Lotus East is a comprehensive enterprise, which deals in an integration of the production, trade, sales and marketing of pharmaceuticals. The Company possesses some of the most advanced pharmaceutical-production equipment used in China, workshops authenticated by the National GMP, a suite of various medicines produced by Lotus East, and a number of high-tech personnel. Lotus East has business and office facilities of 2,000 square meters, warehouse of 1,000 square meters and operates ten retail pharmacies in the Beijing area. Lotus East performs scientific research on new medicines, and the production, wholesale and retail sale of medicines through 10 retail pharmacy location through Beijing. For more information, visit http://www.LotusEast.com .
Safe Harbor Statement
Certain statements set forth in this press release constitute ''forward-looking statements". Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "should," "could," ''would,'' ''may'' or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions -- especially those relating to China, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws, restrictions and regulations on doing business in a foreign country, in particular China, and conditions of equity markets. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.
-- FINANCIAL TABLES FOLLOW --
LOTUS PHARMACEUTICALS, INC. AND SUBSIDIARIES Unaudited Consolidated Statements of Operations
Three Months Ended December 31, 2007 2006 (restated) Revenues $ 19,223,779 $ 11,128,000 Cost of Goods Sold 10,940,507 8,647,623 Gross Profit 8,283,272 2,480,377
Operating Expenses Selling 3,595,460 1,839,251 Research and development 862,519 96,833 General and administrative 382,646 684,888 Total operating expenses 4,840,625 2,620,972 Income (Loss) from Operations 3,442,647 (140,595)
Other Income (Expense) Other income (expense) 2,102,115 -- Interest expense, net (427,800) (17,114) Total other income (expense) 1,674,315 (17,114)
Income (Loss) Before Provision for Income Tax 5,116,962 (157,709)
Net Income (Loss) $ 5,116,962 $ (157,709)
Basic Earnings Per Share $ 0.12 $ (0.00) Diluted Earnings Per Share $ 0.12 $ (0.00)
Basic Weighted Average Shares Outstanding 41,678,330 41,280,000 Diluted Weighted Average Shares Outstanding 44,448,330 44,280,000
The Components of Other Comprehensive Income Net Income (Loss) $ 5,116,962 $ (157,709) Foreign currency translation adjustment 927,537 130,223
Comprehensive Income (Loss) $ 6,044,499 $ (27,486)
LOTUS PHARMACEUTICALS, INC. AND SUBSIDIARIES Audited Consolidated Statements of Operations
Years Ended December 31, 2007 2006 (restated) Revenues $ 56,873,115 $ 36,207,689 Cost of Goods Sold 33,678,963 26,129,687 Gross Profit 23,194,152 10,078,002
Operating Expenses Selling 6,460,206 3,030,4216 General and administrative 3,014,002 2,191,400 Research and development 2,411,651 387,337 Total operating expenses 11,885,859 5,609,158 Income from operations 11,308,293 4,468,844
Other Income (Expense) Other income 1,845,416 -- Interest expense, net (1,936,581) (325,824) Total other income (expense) (91,165) (325,824)
Net Income Before Provision for Income Tax 11,217,128 4,143,020
Net Income $ 11,217,128 $ 4,143,020
Basic Earnings Per Share $ 0.27 $ 0.10 Diluted Earnings Per Share $ 0.26 $ 0.10
Basic Weighted Average Shares Outstanding 41,417,434 40,360,530 Diluted Weighted Average Shares Outstanding 43,861,106 40,360,530
The Components of Other Comprehensive Income Net Income $ 11,217,128 $ 4,143,020 Foreign currency translation adjustment 1,480,352 327,568
Comprehensive Income $ 12,697,480 $ 4,470,588
LOTUS PHARMACEUTICALS, INC. AND SUBSIDIARIES Audited Consolidated Balance Sheets December 31, 2007 and 2006
2007 2006 Current Assets (restated) Cash and cash equivalents $ 4,557,957 $ 2,089,156 Accounts receivable, net 20,430,827 7,277,067 Inventories 3,410,739 3,133,677 Prepaid expenses 1,009,382 252,103 Deferred debt costs 29,340 -- Total current assets 29,438,245 12,752,003
Property and equipment, net 6,169,966 5,813,935 Intangible assets, net 1,291,322 1,345,041 Due from related party -- 1,826,626
Total Assets $ 36,899,533 $ 21,737,605
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities Convertible debt, net of debt discount $ 2,561,645 $ -- Accounts payable and accrued expenses 764,491 705,147 VAT and service taxes payable 572,200 2,047,851 Advances from customers 34,531 231,340 Unearned revenue 530,063 426,358 Due to related parties 323,178 925,484 Total current liabilities 4,786,108 4,336,180
LONG-TERM LIABILITIES: Due to related parties 738,300 863,447 Notes payable - related parties 4,738,508 4,729,880
Total Liabilities 10,262,916 9,929,507
Stockholders' Equity Common stock ($.001 par value; 200,000,000 shares authorized; 41,794,200 and 41,280,000 shares issued and outstanding, respectively) 41,794 41,280 Additional paid-in capital 8,095,848 5,965,323 Statutory reserves 2,161,505 769,930 Retained earnings 14,355,913 4,530,360 Other comprehensive gain - 1,981,557 501,205 cumulative foreign currency translation adjustment Total stockholders' equity 26,636,617 11,808,098
Total Liabilities and Shareholders' Equity $ 36,899,533 $ 21,737,065
LOTUS PHARMACEUTICALS, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS
For the Year Ended December 31, 2007 2006 (restated) CASH FLOWS FROM OPERATING ACTIVITIES: Net income $11,217,128 $4,143,020 Adjustments to reconcile net income from operations to net cash provided by (used in) operating activities: Depreciation and amortization 564,607 581,564 Amortization of deferred debt issuance costs 205,379 -- Amortization of debt discount 1,458,484 -- Stock issued for compensation 284,200 -- (Decrease) increase in allowance for doubtful accounts and sales returns (2,385,354) 2,732,889 Forgiveness of income and value-added taxes (2,160,795) -- Changes in assets and liabilities: Accounts receivable (9,764,076) (8,922,247) Inventories (58,942) 3,928,236 Prepaid and other current assets (714,013) (75,155) Other payable -- -- Accounts payable and accrued expenses 27,266 206,516 Value-added and service taxes payable 608,526 1,999,675 Unearned revenue 71,402 200,811 Advances from customers (204,267) 39,333
NET CASH (USED IN) PROVIDED BY OPERATING ACTIVITIES (850,455) 4,834,642
CASH FLOWS FROM INVESTING ACTIVITIES: Collections from related party advances 1,061,009 1,243,742 Purchase of property and equipment (381,772) (1,480)
NET CASH PROVIDED BY INVESTING ACTIVITIES 679,237 1,242,262
CASH FLOWS FROM FINANCING ACTIVITIES: Net proceeds from convertible debt 2,950,000 -- Payment of debt issuance costs (231,526) -- Repayments of related party advances (816,732) (737,291) Repayments of notes payable - related parties 509,351 (3,456,196)
NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES 2,411,093 (4,193,487)
NET INCREASE IN CASH 2,239,875 1,928,222
EFFECT OF EXCHANGE RATE ON CASH 228,926 44,805
CASH - beginning of year 2,089,156 160,934
CASH - end of year $4,557,957 $2,089,156
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Cash paid for: Interest $477,001 $325,824 Income taxes $-- $--
Non-cash investing and financing activities: Due from related party offset against note payable - related parties $813,650 $-- Common stock issued for conversion of convertible debt $230,000 $-- Debt discount for grant of warrants and beneficial conversion feature $1,616,839 $-- Intangible assets for related party liabilities $-- $1,127,551
LOTUS PHARMACEUTICALS, INC. AND SUBSIDIARIES RECONCILIATION OF NON-GAAP FINANCIAL DATA
For the Three Months For the Three Months Ended Ended Adjusted Net income December 31, 2007 December 31, 2006 ($ in thousands except per share data) Diluted Diluted Net Income (Loss) Diluted EPS Net Income EPS Net Income EPS
Allowance for sales returns(2) -- -- (2,200,000) (0.05) Forgiveness of income and value-value added taxes(3) 2,160,795 0.05 -- Amount per consolidated statement of operations 5,116,962 0.12 (157,709) 0.00
(1) Non cash debt financing costs for 2007 includes amortization of debt issue costs of $58,680 and amortization of debt discount of $416,710 (2) Allowance for sales returns related to products sold in the fourth quarter of 2006 and recognized in the second and third quarter of 2007 (3) Tax waiver from the Chinese local government
For the Year ended For the Year ended Adjusted Net income December 31, 2007 December 31, 2006 ($ in thousands except per share data) Diluted Diluted Net Income (Loss) Diluted EPS Net Income EPS Net Income EPS
Allowance for sales returns(2) 2,200,000 0.05 (2,200,000) 0.06 Forgiveness of income and value-value added taxes(3) 2,160,795 0.05 -- -- Amount per consolidated statement of operations 11,217,128 0.26 4,143,020 0.10
(1) Non cash debt financing costs for 2007 includes amortization of debt issue costs of $205,379 and amortization of debt discount of $1,458,484 (2) Allowance for sales returns related to products sold in the fourth quarter of 2006 (3) Tax waiver from the Chinese local government
For more information, please contact:
Lotus Pharmaceuticals, Inc. Mr. Adam Wasserman, CFO Tel: +1-877-801-0344 Email: info*LotusEast.com
CCG Elite Investor Relations Inc. Mr. Crocker Coulson, President Tel: +1-646-213-1915 (New York) Email: crocker.coulson*ccgir.com
-------------------------------------------------------------------------------- Source: Lotus Pharmaceuticals, Inc.
-------------------- In the end, trust only yourself when trading stocks. Posts: 2048 | From: Texas | Registered: Feb 2006
| IP: Logged |
posted
Volume of 400K! Decent but needs more. Hoping volume does not dry up tomorrow. If volume increases tomorrow watch out. This thing will take off if just one institution starts buying! On the positive its only about a month till they report Q1! If its anything like this quarter it will have to get noticed!
Posts: 1458 | From: Ohio | Registered: Mar 2004
| IP: Logged |
posted
Volume dropped a bit but it was strong the last half an hour. Also closed at high of the session which is definetly bullish considering all day it was between .91 and .94. Managed to close at .99!
Posts: 1458 | From: Ohio | Registered: Mar 2004
| IP: Logged |
posted
Bought in today at $1.01 based on EPS, revenues, growth. However, something seems rotten here trading at like 2X forward P/E. Also seems either company or some big boys selling a ton of shares, because this should move much better on this volume.
Posts: 6266 | Registered: Jun 2004
| IP: Logged |
posted
Its GTEC selling shares. They still owned 3.2 million shares as of the last 10K. This is down from over 6.7 million last year.
Posts: 1458 | From: Ohio | Registered: Mar 2004
| IP: Logged |
Speedhaul Holdings, to be known as Gold Horse International, Inc., and Lotus Pharmaceuticals, Inc. (OTC BB:LTUS.OB - News) represent residual holdings that Genesis manages on behalf of its shareholders. The private-to-public program is no longer an ongoing profit center for Genesis Pharmaceutical Enterprises, Inc.
So from what I can understand they want to focus on there business so the are divesting all of there holdings. But this is only my understanding.
Posts: 1458 | From: Ohio | Registered: Mar 2004
| IP: Logged |
posted
Up over 7% today on about 250,000 shares traded. Thats higher volume then yesterday.
Posts: 1458 | From: Ohio | Registered: Mar 2004
| IP: Logged |
posted
Volume has dried up. Will probably have to wait until end of May (when they release Q1) for improvement!
Posts: 1458 | From: Ohio | Registered: Mar 2004
| IP: Logged |
posted
Volume above 500K and up another 5%!! Someone is accumulating. Hopefully its an institution!
Posts: 1458 | From: Ohio | Registered: Mar 2004
| IP: Logged |
posted
Q1 results should be annouced any day now. Has come back to $1.05. Volume has dried up. I am looking for earnings growth of over 100%! Eps of at least .04.
Posts: 1458 | From: Ohio | Registered: Mar 2004
| IP: Logged |
posted
filed 5 day extension today(which they always do). So earnings should be out in 5 days. Thats May 21 which is the same day they released them last year!
Posts: 1458 | From: Ohio | Registered: Mar 2004
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
